Dillon Michael P. 4
4 · IDEAYA Biosciences, Inc. · Filed Oct 7, 2021
Insider Transaction Report
Form 4
Dillon Michael P.
SVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2021-10-04$26.62/sh−1,000$26,621→ 78,789 total - Exercise/Conversion
Common Stock
2021-10-04$11.08/sh+1,500$16,620→ 80,289 total - Sale
Common Stock
2021-10-04$25.85/sh−500$12,924→ 79,789 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-10-04−1,500→ 23,437 totalExercise: $11.08Exp: 2029-03-13→ Common Stock (1,500 underlying)
Footnotes (4)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades in prices ranging from $25.39 to $26.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This transaction was executed in multiple trades in prices ranging from $26.42 to $26.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.